Ambrx’ platform will be used to develop a product that has improved biological properties over the FGF-21.
Ambrx and Merck & Co. are collaborating on the development of a therapeutic protein with properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders.
Both parties will utilize Ambrx’ protein technology, ReCODE™, to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.
The collaboration includes an upfront and R&D payments from Merck. Additionally, Ambrx will be eligible to receive future milestone fees associated with research, development, and commercialization of a drug candidate along with royalties on net sales. The firm also has the right to exercise an end of Phase II profit sharing option.